title: [Cyproterone acetate improves beta-cell function in postmenopausal women with diabetes mellitus type 2].
abstract: Menopause is associated with two main risk factors for the development of type 2 diabetes mellitus--impaired beta-cell insulin secretion and insulin resistance. Physiologically estrogens improve carbohydrate metabolism, but this is not the case with different progestogens. The aim of the present study was to evaluate the effect of Cyproterone acetate (a progestogen with antiandrogenic activity) on insulin secretion, peripheral insulin sensitivity, lipid parameters and parameters of oxidative stress. Seven type 2 diabetic females, of mean age 55.4 +/- 4.7 years and mean BMI 30.8 +/- 9.39 kg/m2, in menopause for average 5 years, in good borderline glycaemic control (mean HbAic 7.8%), with dyslipidaemia, normal parameters of calcium and phosphate metabolism and with osteopenia (T-score < 88%) were enrolled in the study. They were treated with Estradiol valerate + Cyproterone acetate (Climen, Schering) for three months. Phases of insulin secretion--first phase (FPIS), second phase (SPIS) and AUC for FPIS and SPIS were assessed during IVGTT. Insulin sensitivity was determined with the manual method of euglycaemic hyperinsulinaemic clamp technique. The postmenopausal diabetic women in the present study were with overweight and obesity; they did not increase their body weight during HRT and even decreased it by mean 0.7%. Insulin secretion improved after Climen--FPIS increased by 16% and SPIS by 44%. Insulin sensitivity increased by 15%; triglycerides decreased by 16% and HDL-cholesterol increased by 27%. Total antioxidant capacity of the serum (TAOK) increased by 7%. The favourable effect on the pathophysiological mechanisms improved metabolic control--HbAic was reduced by mean 3% after 3 months. In conclusion, our results suggest that HRT with the progestogen Cyproterone acetate (Climen) should be preferred in postmenopausal type 2 diabetic females with predominant beta-cell insulin secretion defect.
authors.forename: A M
authors.initials: AM
authors.lastname: Borisova
authors.forename: Ts
authors.initials: Ts
authors.lastname: Tankova
authors.forename: P
authors.initials: P
authors.lastname: Kamenova
authors.forename: L
authors.initials: L
authors.lastname: Dakovska
authors.forename: G
authors.initials: G
authors.lastname: Kirilov
authors.forename: N
authors.initials: N
authors.lastname: Genov
authors.forename: R
authors.initials: R
authors.lastname: Kovacheva
authors.forename: B
authors.initials: B
authors.lastname: Milcheva
authors.forename: D
authors.initials: D
authors.lastname: Koev
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015519:Bone Density / Q000502:physiology; D017373:Cyproterone Acetate / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism* / Q000503:physiopathology; D015914:Estrogen Replacement Therapy; D005260:Female; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D008875:Middle Aged; D017698:Postmenopause
chemical_list: D001786:Blood Glucose; D007328:Insulin; D017373:Cyproterone Acetate